How do you pay?

How to pay the least

Ask for the cash price

Paxlovid

No generic is sold yet.

  1. Ask your pharmacy for Paxlovid’s cash price, and one or two other pharmacies too.
  2. Paxlovid’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand namePaxlovid
Authorized genericnirmatrelvir and ritonavir
Regular genericnirmatrelvir and ritonavir
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone sold yet
Same as Paxlovid?
The original
–
–

Brand nameThe maker’s card

PAXCESS Co-Pay Savings Program

Savings card from Pfizer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

The card takes up to $1,000 a year off your co-pay.

Sign up on paxlovid.com 

Or call 1-877-219-7225. See the offer on paxlovid.com

In the maker’s words

“Eligible commercially insured patients may access PAXLOVID for as little as $0, and eligible Medicare, Medicaid, and uninsured patients may access PAXLOVID for free.”

From the maker’s offer on paxlovid.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Paxlovid itself, from the same company, sold without the brand name, and usually for less. For now Paxlovid is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

PAXLOVID which includes nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro: also referred to as 3CLpro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. Limitations of Use

PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

Source: the FDA label for Paxlovid (Pfizer Laboratories Div Pfizer Inc), February 19, 2026. Full label on DailyMed 

Good to know